UTHealth has created a clinic that will provide a myriad of expert physicians for patients still dealing with COVID-19 symptoms. Photo via Getty Images

Houston's first clinic for treatment of patients still coping with symptoms of COVID-19 has opened at UT Physicians, the clinical practice of McGovern Medical School at University of Texas Health Science Center at Houston.

The clinic, part of the new UTHealth COVID-19 Center of Excellence, is staffed by specialists in cardiology, general medicine, neurology, infectious disease, pulmonology, psychiatry, and otorhinolaryngology (ear, nose, and throat). Telehealth and in-person visits are available.

"The UTHealth COVID-19 Center of Excellence brings together our university's experts in adult and pediatric specialty care, public health, biomedical research, and big data analytics — all working to provide the best outcomes for our patients, the best public health and prevention practices for our community, and the best therapies for the virus' short- and long-term impacts," Dr. Giuseppe Colasurdo, president of UTHealth, says in an October 15 release.

Among other things, the COVID-19 Center of Excellence will work on developing reliable testing for the coronavirus, authenticating effective therapies, applying analytics and artificial intelligence to care and research, and collecting virus samples for a "biobank" to study how genetics affects the virus' severity.

Since the emergence of the coronavirus pandemic, scientists and physicians at McGovern Medical School have led clinical trials and treatment protocols, including one of the world's first double-lung transplants for a coronavirus patient. UTHealth is participating in some of the largest national clinical trials to help COVID-19 patients heal, such as studies to prevent progression of the disease and studies seeking proven treatments for critically ill patients.

In one of the country's first randomized clinical trials of its kind, an $8 million grant from the National Institutes of Health is financing a UTHealth study of whether infusions of convalescent plasma can prevent the progression of COVID-19. Another research team is evaluating whether an oral HIF (hypoxia-inducible factor) inhibitor can protect the lungs of COVID-19 patients. The inhibitor is designed to trigger the body's protective response to low oxygen levels.

At the same time, researchers at UTHealth's Cizik School of Nursing are studying the socioeconomic and mental health effects of the virus on Hispanics, while members of the MD Anderson UTHealth Graduate School of Biomedical Sciences are exploring how the time of day a medication is taken might help a COVID-19 patient. In addition, experts at UTHealth's School of Biomedical Informatics are using big data to fight COVID-19.

"Within our six schools, we have the broad expertise that has positioned us as one of the few universities to help our community, Texas and the country through the pandemic and beyond," says Michael Blackburn, executive vice president and chief academic officer of UTHealth. "That starts with amazing clinical care, COVID-19 trials, real-time translational research, and expert knowledge from our public health leaders."

The School of Public Health is leading establishment of a study to be conducted with partners throughout Southeast Texas to assess the virus' long-term consequences, determine factors that contribute to severe outcomes, and enable UTHealth experts to develop and use treatments more effectively. In addition, a community information exchange will be built to connect vulnerable populations with healthcare and social service providers.

"In these unprecedented times, the six schools at UTHealth are rapidly evolving the science and medical care for patients with COVID-19 and our community," says Dr. Bela Patel, vice dean of healthcare quality at McGovern Medical School. "Prevention, new therapeutics, and post-COVID-19 care for our patients with prolonged COVID-19 disease is the mission for the UTHealth Center of Excellence for COVID-19."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Health tech startup launches Houston study improve stroke patients recovery

now enrolling

A Houston-born company is enrolling patients in a study to test the efficacy of nerve stimulation to improve outcomes for stroke survivors.

Dr. Kirt Gill and Joe Upchurch founded NeuraStasis in 2021 as part of the TMC Biodesign fellowship program.

“The idea for the company manifested during that year because both Joe and I had experiences with stroke survivors in our own lives,” Gill tells InnovationMap. It began for Gill when his former college roommate had a stroke in his twenties.

“It’s a very unpredictable, sudden disease with ramifications not just for my best friend but for everyone in his life. I saw what it did to his family and caregivers and it's one of those things that doesn't have as many solutions for people to continue recovery and to prevent damage and that's an area that I wanted to focus myself on in my career,” Gill explains.

Gill and Upchurch arrived at the trigeminal and vagus nerves as a potential key to helping stroke patients. Gill says that there is a growing amount of academic literature that talks about the efficacy of stimulating those nerves. The co-founders met Dr. Sean Savitz, the director of the UTHealth Institute for Stroke and Cerebrovascular Diseases, during their fellowship. He is now their principal investigator for their clinical feasibility study, located at his facility.

The treatment is targeted for patients who have suffered an ischemic stroke, meaning that it’s caused by a blockage of blood flow to the brain.

“Rehabilitation after a stroke is intended to help the brain develop new networks to compensate for permanently damaged areas,” Gill says. “But the recovery process typically slows to essentially a standstill or plateau by three to six months after that stroke. The result is that the majority of stroke survivors, around 7.6 million in the US alone, live with a form of disability that prevents complete independence afterwards.”

NeuraStasis’ technology is intended to help patients who are past that window. They accomplish that with a non-invasive brain-stimulation device that targets the trigeminal and vagus nerves.

“Think of it kind of like a wearable headset that enables stimulation to be delivered, paired to survivors going through rehabilitation action. So the goal here is to help reinforce and rewire networks as they're performing specific tasks that they're looking to improve upon,” Gill explains.

The study, which hopes to enroll around 25 subjects, is intended to help people with residual arm and hand deficits six months or more after their ischemic stroke. The patients enrolled will receive nerve stimulation three times a week for six weeks. It’s in this window that Gill says he hopes to see meaningful improvement in patients’ upper extremity deficits.

Though NeuraStasis currently boasts just its two co-founders as full-time employees, the company is seeing healthy growth. It was selected for a $1.1 million award from the National Institutes of Health through its Blueprint MedTech program. The award was funded by the National Institute of Neurological Disorders and Stroke. The funding furthers NeuraStasis’ work for two years, and supports product development for work on acute stroke and for another product that will aid in emergency situations.

Gill says that he believes “Houston has been tailor-made for medical healthcare-focused innovation.”

NeuraStasis, he continues, has benefited greatly from its advisors and mentors from throughout the TMC, as well as the engineering talent from Rice, University of Houston and Texas A&M. And the entrepreneur says that he hopes that Houston will benefit as much from NeuraStasis’ technology as the company has from its hometown.

“I know that there are people within the community that could benefit from our device,” he says.

Texas Space Commission launches, Houston execs named to leadership

future of space

Governor Greg Abbott announced the Texas Space Commission, naming its inaugural board of directors and Texas Aerospace Research and Space Economy Consortium Executive Committee.

The announcement came at NASA's Johnson Space Center, and the governor was joined by Speaker Dade Phelan, Representative Greg Bonnen, Representative Dennis Paul, NASA's Johnson Space Center Director Vanessa Wyche, and various aerospace industry leaders.

According to a news release, the Texas Space Commission will aim to strengthen commercial, civil, and military aerospace activity by promoting innovation in space exploration and commercial aerospace opportunities, which will include the integration of space, aeronautics, and aviation industries as part of the Texas economy.

The Commission will be governed by a nine-member board of directors. The board will also administer the legislatively created Space Exploration and Aeronautics Research Fund to provide grants to eligible entities.

“Texas is home to trailblazers and innovators, and we have a rich history of traversing the final frontier: space,” Lieutenant Governor Dan Patrick says in a news release. “Texas is and will continue to be the epicenter for the space industry across the globe, and I have total confidence that my appointees to the Texas Space Commission Board of Directors and the Texas Aerospace Research and Space Economy Consortium Executive Committee will ensure the Texas space industry remains an international powerhouse for cutting-edge space innovation.”

TARSEC will independently identify research opportunities that will assist the state’s position in aeronautics research and development, astronautics, space commercialization, and space flight infrastructure. It also plans to fuel the integration of space, aeronautics, astronautics, and aviation industries into the Texas economy. TARSEC will be governed by an executive committee and will be composed of representatives of each higher education institution in the state.

“Since its very inception, NASA’s Johnson Space Center has been home to manned spaceflight, propelling Texas as the national leader in the U.S. space program,” Abbott says during the announcement. “It was at Rice University where President John F. Kennedy announced that the U.S. would put a man on the moon—not because it was easy, but because it was hard.

"Now, with the Texas Space Commission, our great state will have a group that is responsible for dreaming and achieving the next generation of human exploration in space," he continues. "Texas is the launchpad for Mars, innovating the technology that will colonize humanity’s first new planet. As we look into the future of space, one thing is clear: those who reach for the stars do so from the great state of Texas. I look forward to working with the Texas Space Commission, and I thank the Texas Legislature for partnering with industry and higher education institutions to secure the future of Texas' robust space industry."

The Houston-area board of directors appointees included:

  • Gwen Griffin, chief executive officer of the Griffin Communications Group
  • John Shannon, vice president of Exploration Systems at the Boeing Company
  • Sarah "Sassie" Duggleby, co-founder and CEO of Venus Aerospace
  • Kirk Shireman, vice president of Lunar Exploration Campaigns at Lockheed Martin
  • Dr. Nancy Currie-Gregg, director of the Texas A&M Space Institute

Additionally, a few Houstonians were named to the TARSEC committee, including:

  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace
  • Matt Ondler, president and former chief technology officer at Axiom Space
  • Jack “2fish” Fischer, vice president of production and operations at Intuitive Machines
  • Brian Freedman, president of the Bay Area Houston Economic Partnership and vice chairman of Wellby Financial
  • David Alexander, professor of physics and astronomy and director of the Rice Space Institute at Rice University

To see the full list of appointed board and committee members, along with their extended bios, click here.